Discover
Alofisel (darvadstrocel) / TakedaADMIRE-CD-II: Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) (clinicaltrials.gov) - Jun 9, 2020 - P3; N=554; Recruiting; Sponsor: Tigenix S.A.U.; Active, not recruiting --> Recruiting
Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic UniversityTOFAST: Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Jun 9, 2020 - P; N=280; Not yet recruiting; Sponsor: Pfizer
Humira (adalimumab) / Eisai, AbbVieAbbVie dodges antitrust challenge to Its Humira ‘patent thicket’ (Bloomberg Law) - Jun 8, 2020 - "AbbVie Inc., Amgen Inc., a Samsung subsidiary, and Novartis unit Sandoz Inc. don’t have to face antitrust claims over patent infringement settlements that delayed generic competition for the blockbuster arthritis drug Humira, a Chicago federal judge ruled Monday....Dismissing the case, Shah noted that patent applications are normally covered by the Noerr-Pennington doctrine, which shields companies from antitrust liability for petitioning the government."
CERC-002 / Kyowa Hakko Kirin, Sanofi, CerecorCerecor Inc. announces proposed public offering of common stock (GlobeNewswire) - Jun 8, 2020 - "Cerecor Inc....announced today that it intends to offer for sale shares of its common stock in an underwritten public offering....Cerecor intends to use the net proceeds of the offering for general corporate purposes and working capital, primarily to support the ongoing clinical development of key assets within its pipeline and for general and administrative expenses."
